Events
Adocia, a clinical stage biopharmaceutical company focused on diabetes treatment and other metabolic diseases with innovative formulations of approved proteins, announced its financial calendar for 2020.
Atlantic Healthcare plc, a specialist pharmaceutical company focused on acquiring, developing and commercialising therapeutics that address unmet patient needs and rare diseases, announces it will present at the Biotech Showcase conference, held in San Francisco from January 13-15, 2020.
UK based MR Solutions presented a simultaneous 7T PET/MRI preclinical imaging system optimized for nanoparticle imaging to the first joint annual congress of the French Nanomedicine Society, and the French national Competency Cluster in Nanoscience C’Nano which was held in Dijon in early December.
Helsinn, a Swiss pharmaceutical group focused on building quality cancer care products, is presenting a scientific poster assessing acute care involving chemotherapy-induced nausea and vomiting amongst breast cancer patients receiving various treatments for CINV prophylaxis including NEPA, at the San Antonio Breast Cancer Symposium.
Munich/ Martinsried Medigene AG, a clinical stage immuno-oncology company focusing on the development of T cell immunotherapies, announces that Medigene’s researchers presented clinical immune monitoring data obtained during the first year of treatment from the ongoing Phase I/II clinical trial with Medigene’s DC vaccine for the treatment of acute myeloid leukemia at the 61st ASH Annual Meeting.
Data on 52 patients in the 145-patient clinical trial highlight ADCT-402 (loncastuximab tesirine) continues to demonstrate anti-tumor activity and manageable toxicity in heavily pretreated patients
PHARMASEAL, a new provider of clinical trial management and governance solutions to enter the market, announces that is has won Start-Up of the Year in the 2019 Medilink East Midlands Business Awards.
The Dutch company Xenikos B.V., which develops innovative immunotherapies for treating patients with severe immune disease and post-transplant rejection, reports data from an expanded access program using T-Guard to treat steroid-refractory acute graft-versus-host disease in patients following allogeneic stem cell transplantation.
BioIVT announced that it is hosting a drug discovery webinar that will discuss how small interfering RNA molecules can be used to selectively suppress hepatic genes in an in vitro liver model and advance the development of small molecule and nucleic acid therapies.
Alector, Inc., a clinical stage biotechnology company pioneering immuno-neurology, reported safety and biomarker data from the single ascending dose phase of the INVOKE Phase1 study of its product candidate, AL002, in healthy volunteers.
PRESS RELEASES